跳至主要内容
临床试验/NCT02726477
NCT02726477Unknown不适用

Efficacy and Safety of Wuling San on Breast Cancer-related Lymphedema

Fourth Affiliated Hospital of Guangxi Medical University3 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2016年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
200
试验地点
3
主要终点
volume changes % measured by perometry

研究概览

简要总结

The purpose of this study is to assess the efficacy and safety of Wuling San, a traditional Chinese medicine, in reducing arm volume excess in women with stage I-II breast cancer related unilateral lymphedema.

详细描述

The investigators will aim to enroll 200 female adult patients (aged between 20 and 40 years) of all ethnicities/races, who have been referred to the Fourth Affiliated Hospital of Guangxi Medical University for breast cancer related unilateral lymphedema. The investigators will be using a standardized data collection form in this study, where standard of care will be practiced and the patients are not placed at additional risk from participating in this study. However, as the investigators are collecting data prospectively, all participants will sign consent.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Women completed all primary and adjuvant treatments (surgery, chemotherapy, radiotherapy)
  • age 20-40 with unilateral BCRL, stage I or II, BMI of 18-25
  • Volume difference ≥300 mL between the normal and lymphedematous upper extremity based on perometry evaluation
  • No evidence of breast cancer recurrence
  • At least 6 months postoperative from axillary lymph node dissection

排除标准

  • Bilateral lymphedema or stage III lymphedema
  • History of bilateral axillary lymph node dissection
  • Recent history of cellulitis in the affected extremity (within last 3 months)
  • Recurrent breast cancer or other malignancy
  • Current (within last month) use of chemotherapy for breast or other malignancy
  • Current (within last 3 months) use of radiation for breast or other malignancy
  • Recent (within last month) or current intensive MLD and/or short stretch bandage use
  • Unstable lymphedema (i.e. worsening symptoms/measurements in the past 3 months)
  • Pregnant or nursing (lactating) women
  • Patients that take drugs like diosmin at the time of enrollment, or within 30 days.
  • Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
  • Unable to comply with the protocol, measurement and follow-up schedule.

研究组 & 干预措施

Wuling San

Experimental

This is a double-blinded, randomized placebo-controlled, multi-center clinic trial, using before and after treatment measurements.

A total of 200 clinical diagnosed BCRL participants with affected arm circumference 10-40% larger than unaffected arm, are randomly allocated to two groups: the Wuling San group or the placebo group, where the intervention group administers Wuling San, at a dosage of 1g/kg, twice a day for six weeks. The primary outcome measurement will be the percentage of limb volume changes measured by perometry.

干预措施: Wuling San (Drug)

placebo

Placebo Comparator

A total of 200 clinical diagnosed BCRL participants with affected arm circumference 10-40% larger than unaffected arm, are randomly allocated to two groups: the Wuling San group or the placebo group, where the placebo group administers a placebo powder, at a dosage of 1g/kg, twice a day for six weeks. The primary outcome measurement will be the percentage of limb volume changes measured by perometry.

干预措施: placebo (Drug)

结局指标

主要结局

volume changes % measured by perometry

时间窗: baseline and 2 months

Volume changes in the arm after the therapy will be calculated using the methods established by Anderson et al (2000). Briefly, the difference in volume measurements between the normal and lymphedematous arms at baseline will be compared to the volume differential after drug treatment (i.e volume excess) using the following formula: Change in absolute edema=(Vo-Vc)B-(Vo-Vc)3 months/(Vo-Vc)B Change in ln ratio=ln (Vo/Vc)B-ln (Vo/Vc)3 months. Vo is the volume of the lymphedema arm. Vc is the volume of the contralateral arm. Andersen, L., Højris, I., Erlandsen, M., \& Andersen, J. (2000). Treatment of breast-cancer-related lymphedema with or without manual lymphatic drainage: a randomized study\[J\]. Acta Oncologica, 2000, 39(3): 399-405.

次要结局

  • adverse events(baseline and 2 months)

研究者

发起方
Fourth Affiliated Hospital of Guangxi Medical University
申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验